Among the three lung cases, the lung cancer patient (9) with a single DCTN1–ALK mutation received crizotinib orally at a dose of 250 mg twice daily, which resulted in a significant symptomatic improvement and radiographic response after 3 months of therapy. This evidence concerns the gene ALK and lung carcinoma.